Cancer-associated bone disease

Current Osteoporosis Reports

Volumn 5, Issue 3, 2007, Pages 120-127

  Brown, Sue A ^a   Guise, Theresa A ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKYLATING AGENT; ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; EXEMESTANE; GLUCOCORTICOID; IFOSFAMIDE; LETROZOLE; METHOTREXATE; PAMIDRONIC ACID; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

BONE DISEASE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG SAFETY; FRACTURE; HORMONAL THERAPY; HUMAN; LIFESTYLE MODIFICATION; METASTASIS; MULTIPLE MYELOMA; OSTEOLYSIS; OSTEOPOROSIS; PROSTATE CANCER; REVIEW; RISK FACTOR; SIDE EFFECT;

EID: 35348910350     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-007-0027-8     Document Type: Review

References (53)

1. Kanis JA, Oden A, Johnell O, et al.: The components of excess mortality after hip fracture. Bone 2003, 32:468-473.
2. Oefelein MG, Ricchiuti V, Conrad W, et al.: Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002, 168:1005-1007.
3. Roudier MP, Vesselle H, True LD, et al.: Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results. Clin Exp Metastasis 2003, 20:171-180.
4. Coleman RE, Major P, Lipton A, et al.: Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005, 23:4925-4935.
5. Guise TA, Mohammad KS, Clines G, et al.: Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006, 12:6213s-6216s.
6. Roodman GD: Mechanisms of bone metastasis [review]. N Engl J Med 2004, 350:1655-1664. Excellent review of the mechanisms underlying tumor cell metastasis to bone.
7. Clines GA, Mohammad KS, Bao Y, et al.: Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Mol Endocrinol 2007, 21:486-498.
8. Tian E, Zhan F, Walker R, et al.: The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003, 349:2483-2494.
9. Padalecki SS, Carreon MR, Grubbs B, et al.: Androgen deprivation causes bone loss and increased prostate cancer metastases to bone: prevention by zoledronic acid [abstract]. J Bone Miner Res 2002, 17:S310.
10. Lein M, Wirth M, Miller K, et al.: Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progression. Eur Urol 2007, In press.
11. Pfeilschifter J, Diel IJ: Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 2000, 18:1570-1593.
12. Hirbe A, Morgan EA, Uluckan O, Weilbaecher K: Skeletal complications of breast cancer therapies [review]. Clin Cancer Res 2006, 12:6309s-6314s.
13. Chen Z, Maricic M, Bassford TL, et al.: Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study. Arch Intern Med 2005, 165:552-558.
14. Kanis JA, McCloskey EV, Powles T, et al.: A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 1999, 79:1179-1181.
15. Powles TJ, Hickish T, Kanis JA, et al.: Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996, 14:78-84.
16. Sverrisdottir A, Fornander T, Jacobsson H, et al.: Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol 2004, 22:3694-3699.
17. Howell A, Cuzick J, Baum M, et al.: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365:60-62. Landmark randomized clinical trial comparing 5 years of therapy with anastrozole alone, tamoxifen alone, or both in combination, establishing efficacy of aromatase inhibition.
18. Perez EA, Josse RG, Pritchard KI, et al.: Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006, 24:3629-3635.
19. Coates AS, Keshaviah A, Thurlimann B, et al.: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007, 25:486-492.
20. Coleman RE, Banks LM, Girgis SI, et al.: Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007, 8:119-127.
21. Eastell R, Hannon RA, Cuzick J, et al.: Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 2006, 21:1215-1223.
22. Gonnelli S, Cadirni A, Caffarelli C, et al.: Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. Bone 2007, 40:205-210.
23. Smith MR: Therapy insight: osteoporosis during hormone therapy for prostate cancer. Nat Clin Pract Urol 2005, 2:608-615.
24. Smith MR, McGovern FJ, Zietman AL, et al.: Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001, 345:948-955.
25. Smith MR, Eastham J, Gleason DM, et al.: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003, 169:2008-2012.
26. Maillefert JF, Sibilia J, Michel F, et al.: Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999, 161:1219-1222.
27. Smith MR, McGovern FJ, Fallon MA, et al.: Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer 2001, 91:2238-2245.
28. Morote J, Morin JP, Orsola A, et al.: Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology 2007, 69:500-504.
29. Smith MR, Boyce SP, Moyneur E, et al.: Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 2006, 175:136-139; discussion 139.
30. Smith MR, Lee WC, Brandman J, et al.: Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005, 23:7897-7903.
31. Shahinian VB, Kuo YF, Freeman JL, et al.: Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005, 352:154-164.
32. Giuliani N, Rizzoli V, Roodman GD: Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 2006, 108:3992-3996. Comprehensive discussion of the mechanism underlying deficits in bone formation in multiple myeloma.
33. Melton LJ 3rd, Kyle RA, Achenbach SJ, et al.: Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res 2005, 20:487-493.
34. Nelson HD, Helfand M, Woolf SH, et al.: Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002, 137:529-541.
35. Hillner BE, Ingle JN, Chlebowski RT, et al.: American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003, 21:4042-4057.
36. Theriault RL, Biermann JS, Brown E, et al.: NCCN Task Force report: bone health and cancer care. J Natl Compr Canc Netw 2006, 4(suppl 2):S1-S20.
37. Powles T, Paterson A, McCloskey E, et al.: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 2006, 8:R13.
38. Saad F, Gleason DM, Murray R, et al.: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002, 94:1458-1468.
39. Rosen LS, Gordon D, Kaminski M, et al.: Long-term efficacy and safety of zoledronic acid compared with Pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003, 98:1735-1744.
40. Diamond TH, Winters J, Smith A, et al.: The antiosteoporotic efficacy of intravenous Pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 2001, 92:1444-1450.
41. Ryan CW, Huo D, Demers LM, et al.: Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol 2006, 176:972-978.
42. Michaelson MD, Kaufman DS, Lee H, et al.: Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007, 25:1038-1042.
43. Brufsky A, Harker WG, Beck JT, et al.: Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007, 25:829-836.
44. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al.: Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007, 25:820-828.
45. Greenspan SL, Nelson JB, Trump DL, et al.: Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007, 146:416-424.
46. Greenspan SL, Bhattacharya RK, Sereika SM, et al.: Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab 2007, 92:131-136.
47. Vogel VG, Costantino JP, Wickerham DL, et al.: Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006, 295:2727-2741.
48. Guarneri V, Donati S, Nicolini M, et al.: Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 years. Oncologist 2005, 10:842-848.
49. Bamias A, Kastritis E, Bamia C, et al.: Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005, 23:8580-8587.
50. American Dental Association Council on Scientific Affairs: Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc 2006, 137:1144-1150.
51. Woo SB, Hellstein JW, Kalmar JR: Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006, 144:753-761. A retrospective case review summarizing data regarding reports of osteonecrosis of the jaw.
52. Shane E, Goldring S, Christakos S, et al.: Osteonecrosis of the jaw: more research needed. J Bone Miner Res 2006, 21:1503-1505.
53. Lacy MQ, Dispenzieri A, Gertz MA, et al.: Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 2006, 81:1047-1053.